Long-term use of a sensory neuroprosthesis improves function in a patient with peripheral neuropathy: a case report

Diane M. Wrisley, PT, PhD¹,²
Gillian McLean, PT, DPT¹,³
Jennifer Baity, PT, DPT¹,⁴
Lars Oddsson, PhD⁵-⁷

¹Department of Physical Therapy, Wingate University, Wingate, NC
²Doctor of Physical Therapy Program, College of St Mary, Omaha, NE
³Fyzical Therapy & Balance Centers, Las Vegas, NV
⁴OrthoCarolina Outpatient Winston-Salem, Winston-Salem, NC
⁵Department of Rehabilitation Medicine, Medical School, University of Minnesota, Minneapolis, MN, USA
⁶Recanati School of Community Health, Ben Gurion University of the Negev, Israel
⁷RxFunction Inc., Eden Prairie, MN, USA

Address all correspondence to Diane M. Wrisley, PT, PhD, Doctor of Physical Therapy Program, College of St Mary, 4415 Gwen Hartis Ct., Monroe, NC 28110, phone: 757-593-7037, email: dwrisley@csm.edu

Keywords: Balance, sensory substitution, neuroprosthesis, peripheral neuropathy, fall risk, diabetes
Abstract

Background:
Peripheral neuropathy (PN) can result in either partial or complete loss of distal sensation resulting in an increased fall risk. Walkasins® uses a shoe insert to detect the magnitude and direction of sway and sends signals to a leg unit that provides sensory balance cues. The objective of this case report is to describe the long-term influence of the Walkasins® lower limb sensory neuroprosthesis on balance and gait for an individual with diabetic PN.

Case Description:
A fifty-one-year-old male with a 3-year history of PN and a 10-year history of type II diabetes mellitus was fitted with Walkasins® and utilized the shoe inserts 8-10 hours/day for more than 1 year. Although, vibration and tactile thresholds were severely impaired at his 1st metatarsophalangeal joint and the lateral malleolus bilaterally he could perceive tactile stimuli from the Walkasins® above the ankles.

Outcomes:
Following Walkasins® use, his Activities-specific Balance Confidence Scale (ABC) scores improved from 33% to 80%. His mean Vestibular Activities of Daily Living (VADL) scores decreased from 3.54 to 1. His Functional Gait Assessment (FGA) scores increased from 13/30 to 28/30 and his miniBESTest scores improved from 15/28 to 26/28. Gait speed increased from 0.23 m/sec to 1.5 m/sec. The patient described a decrease in pain and cramping throughout his lower extremities and an increase in function.

Discussion:
Gait and balance improved with the use of the Walkasins® and participation in the Neuro Wellness Program. This improvement suggests that the use of sensory substitution devices, such as the Walkasins®, may replace sensory deficits related to gait and balance dysfunction experienced by patients with PN. Further research is needed to determine if other patients will have a similar response and what the necessary threshold of sensory function is to benefit from use of the Walkasins®.
Background and Purpose

Approximately 12% of the adult population in the United States has been diagnosed with diabetes mellitus with the prevalence in adults 45-64 being 17%.\(^1\) The prevalence is rising due to aging, obesity and decreases in physical activity.\(^2\) Thirty to fifty percent of adults with diabetes present with peripheral neuropathy (PN).\(^3\)–\(^6\) The number of people with PN may be higher as many cases are subclinical, undiagnosed, or are underreported.\(^2,7\) Peripheral neuropathy can be either motor, autonomic, sensory or a combination of all three.\(^8\) The majority of people with PN experience autonomic neuropathy with the second most common form being sensory neuropathy. With diabetes, the most common type of PN is sensory.\(^9\) Symptoms of PN include autonomic, motor, and sensory dysfunction resulting in balance and gait impairments. People with PN demonstrate increased sway with their eyes closed and more sway response to visual flow.\(^10,11\) Decreased use of an ankle strategy is also noted as is decreased reaction time which both can increase the risk of falling\(^12\).

Gait speed and stride length are decreased in people with diabetes.\(^13,14\) Persons with PN demonstrate a wide base of support, greater step time variability, greater time spent in double limb support, and impaired pressure distribution of the foot.\(^14,15\) People with painful PN demonstrate greater variability in step length and velocity.\(^13\) Ankle mobility and power are decreased as well.\(^16\) It is thought that the sensory changes that occur with PN contribute to gait impairments.\(^13\)

People with PN have an increased risk of falling.\(^14,17,18\) Approximately 29% of people with diabetic peripheral neuropathy have experienced a fall in the previous 12 months.\(^19\) Peripheral neuropathy is significantly associated with falling and repetitive falling.
risk increases when the person is in pain or experiencing gait and balance dysfunction.\textsuperscript{20} Most falls occur during gait.\textsuperscript{14,17,21}

Although current physical therapy interventions can improve balance and gait function in people with PN, the improvements are only minimal. In two systematic reviews of interventions for diabetic peripheral neuropathy, lower extremity strengthening was given only a fair recommendation\textsuperscript{22,23}. All other interventions, including electrotherapy\textsuperscript{22} and monochromatic light therapy\textsuperscript{22}, had insufficient evidence to recommend them for decreasing pain and increasing function.\textsuperscript{24} Salsabili et al.\textsuperscript{24}, however, found an improvement in Timed “Up and Go” scores and Falls Efficacy Scale scores following 4 weeks of task-oriented gait and balance training in a case series. Timed “Up & Go” scores decreased greater than the Minimal Detectable Change(MDC) from an average of 10 seconds to 7.3 seconds.\textsuperscript{25}

The use of plantar electrical stimulation daily for 6 weeks improved gait (stride velocity and stride time) and balance parameters (sway eyes open) as well as vibratory plantar threshold when compared to a control group that also improved but less than the intervention group.\textsuperscript{26} Gait speeds increased from .87 m/sec to .97 m/sec in the intervention group and from .82 m/sec to .90 m/sec in the control group. Considering such marginal changes in outcomes, interventions that can improve gait and balance function in people with PN is needed. The SENSUS device used in the Najafi et al.\textsuperscript{26} study was a TENS unit applied to the plantar surface for an hour each night.

Vibrotactile sensory substitution devices have been used experimentally to improve gait and balance function in people with various sensory deficits including older adults at risk for falls and vestibular dysfunction.\textsuperscript{27-34} Sensory substitution devices may use
accelerometers and gyroscopes to replace lost vestibular function or foot pressure sensors to replace lost plantar mechanoreceptor function to help determine the body position in space and improve balance. Furthermore, pilot data suggests a possible augmentation effect where gait and balance function may improve although the sense appears clinically intact (e.g. balance-related foot pressure information may enhance balance in patients with vestibulopathy although plantar sensation is intact, and/or vestibular information may enhance balance in PN patients). Currently, sensory substitution devices have been used for short periods of time, usually up to 1 month. Improvements have been demonstrated with carryover up to 6 months but the use of a device long term as a balance prosthesis to improve gait and balance in people with peripheral neuropathy has not been investigated. The purpose of this case report is to describe improvements in gait and balance seen in a patient with diabetic PN when wearing Walkasins®, a sensory neuroprosthesis, long term (6-8 hours/day) for more than 1 year. The device provides directional specific tactile stimuli based on measurements of center of pressure with a sensor embedded insole placed in the shoe. In a recent randomized cross-over trial, short-term in clinic improvements in both FGA and gait speed associated with wearing the Walkasins® device turned on were demonstrated in a group of patients with PN. The frequency of the tactile stimuli provided by the device is in the range of the clinically used 128Hz tuning fork, although the stimulus amplitude is higher. Consequently, patients who may be insensate to the tuning fork may still be able to feel the device stimulus. We hypothesize that the device can replace lost foot pressure sensation with new sensory balance signals that
modulate skin mechanoreceptors using tactile stimulators on the calf proximal to the nerve lesion where the patient’s sensation is still sufficiently intact.\textsuperscript{27,36}

**Case Description: Patient History and Systems Review**

The patient was a 51-year-old male who was referred for physical therapy due to balance and gait difficulties secondary to diabetic PN. He was referred to the Neurologic Wellness Program at Wingate University. The Neurological Wellness Program is a student run (pro bono) clinic that provides exercise, gait, and balance training to people with neurological disorders who do not have health insurance or have exhausted their insurance.

His primary complaint was that his feet were numb. His past medical history includes a 10-year history of type II Diabetes Mellitus, well-controlled with medication, mild back pain, peripheral neuropathy, high blood pressure and kidney failure. He denied any falls in the past year. He complained of not being able to feel his feet, walking on bricks, tingling and pain. He had a diagnosis of primary sensory PN with moderate pain and generalized weakness. Prior to the diagnosis of PN, he was very active playing 20 hours of tennis per week, rollerblading and playing basketball. He was a truck driver for many years prior to his diagnosis and had to stop driving as he could not feel his feet.

He was alert and oriented x3, appeared cognitively intact and was a good historian. His medication included 81 mg aspirin, sertraline, Lisinopril, meclizine (due to generalized dizziness), pravastatin, chlorpromazine, Lyrica, omeprazole, Apidra, Lantus, iron, vitamin C, B12, and D3. His blood pressure was 150/98 with O2 saturation of 98%. His integumentary system was normal as was his range of motion except for ankle
dorsiflexion to neutral bilaterally. Strength was generally 4/5 with the exception of ankle dorsiflexion which was 3+/5 bilaterally. He ambulated approximately 0.25 miles in the community with a straight cane and was independent in all mobility and ADLs. His light touch and sharp/dull sensation was impaired below the knee bilaterally. He was unable to detect the 50g monofilament below the knee but was able to detect the 2 g above the knee. He was unable to detect the 128 Hz tuning fork at the great toe or the lateral malleolus, but it was intact at the knee bilaterally.

Due to the results of the systems review and observation of his gait into the clinic the following special tests were completed. The Activities-specific Balance Confidence Scale (ABC)\textsuperscript{37}, The Vestibular Activities of Daily Living Scale (VADL)\textsuperscript{38}, 20’ gait speed, Functional Gait Assessment (FGA)\textsuperscript{39}, miniBESTest\textsuperscript{40}, Timed “Up & Go” (TUG)\textsuperscript{41} and cognitive TUG\textsuperscript{42} were performed. The results of his initial scores on these tests is illustrated in Figures 1-3.

The Activities-specific Balance Confidence (ABC) test is a 16 item self-efficacy questionnaire that quantifies how confident people are in their ability to balance during the activities.\textsuperscript{37} The ABC is scored on a mean with scores ranging from 0 to 100 with higher scores indicating more confidence. The ABC is reliable and valid.\textsuperscript{37,43-46} The minimal detectable change (MDC) of the ABC is reported to be 11 -15 points depending on the population.\textsuperscript{43,44,47} The patient’s score on the ABC prior to intervention was 32%.

The Vestibular Activities of Daily Living Scale (VADL) was developed to quantify a person’s ability to perform daily activities and perception of assistance needed during functional activities that challenge balance.\textsuperscript{38} It contains 28 items ranging from bed
mobility to driving a car. The VADL was developed to be scored on a median so that an
item can be skipped without affecting the score. We scored it on both a median and
mean to increase its responsiveness. The reliability and validity of the VADL has been
demonstrated in subjects with vestibular dysfunction although an MDC has not been
established.\textsuperscript{38,48} The patient’s mean score on the VADL prior to intervention was 3.5.

Gait speed was calculated on a 20’ walkway with approximately 4’ acceleration and
deceleration space. Calculation of gait speed is considered reliable and valid.\textsuperscript{49-51} A gait
speed of 1.2 m/sec is necessary to cross the street.\textsuperscript{52} The MDC for gait speed is .09
m/s for people with Parkinson Disease\textsuperscript{50} and for those with Alzheimer’s Disease,\textsuperscript{51} and
.109 m/s in older adults.\textsuperscript{53} The patient’s preferred gait speed was 0.21 m/s prior to
intervention. He ambulated with a straight cane in the community.

The Functional Gait Assessment (FGA) was developed to quantify gait tasks in people
with vestibular dysfunction.\textsuperscript{54} It includes 10 tasks, including gait at normal, slow and fast
speeds, gait with head turns, turning, stepping over obstacles, walking tandem, eyes
closed, backwards, and stairs, rated on an ordinal scale. It has been shown to be
reliable and valid in many populations.\textsuperscript{39,55-62} The MDC of the FGA has been calculated
to be 4 points in people with Parkinson’s Disease\textsuperscript{58} and 6 points in people with
vestibular disorders.\textsuperscript{57} The Minimal Clinically Important Difference in community
dwelling older adults is 4.\textsuperscript{63} Scores of less than 22/30 indicate increased fall risk in
community dwelling older adults.\textsuperscript{60} The patient’s FGA score prior to intervention
was 13/30.

The mini-BESTest was developed to guide treatment for balance disorders. It is a
revision of the BESTest to decrease the time for administration. It contains 14 items
scored on an ordinal scale of 0-2. It has been shown to be reliable and valid in various populations. Score of less 16 than indicate increased risk of falling in older adults. The MDC for the mini-BESTest is 3.5 points in people with balance deficits. The patient’s mini-BESTest score prior to intervention was 15/28.

Timed “Up & Go” (TUG) is the time it takes a patient to stand from sitting in a chair, walk 3 meters, turn, walk back to the chair and sit down. Times of greater than 11 seconds indicate increased risk of falls in older, community dwelling older adults. The MDC for the Timed “Up & Go” is 1 sec. The cognitive Timed “Up & Go” (cTUG) requires that a cognitive task such as counting backwards by 3’s is performed while completing the test. A 10% difference between scores on the TUG and the cTUG is considered abnormal. His TUG score was 26 seconds and his cognitive TUG was 37 seconds prior to intervention.

Intervention

The Walkasins® is a sensory neuroprosthesis that is intended to replace nerve function used to detect and signal balance related foot pressure sensation that is lost in patients with PN. It is indicated for use by individuals with lower limb sensory peripheral neuropathy who present with gait and balance impairments and are at high risk of falls. Pressure sensors embedded in shoe inserts measure plantar pressure, an embedded microprocessor and software estimates center of pressure parameters and activates a relevant tactile actuator around the calf providing directional specific information on center of pressure sway to help indicate the position of the body in space. During walking, relevant events of the gait cycle are signaled including heel strike and toe off
allowing identification of the stance and swing phases of gait. The device is currently being investigated in a multi-site long-term clinical trial in a cohort of patients with PN (walk2Wellness, clinicaltrials.gov #NCT03538756). Previous short-term studies including a recent in clinic randomized cross-over trial showed short-term improvements in gait and balance function.

The patient had been participating in a student run, pro bono neurological wellness program for 2 times a week over a period of 5 months and was receiving gait and balance training prior to the intervention with the Walkasins®. Although he had seen some improvement in his gait and balance, he was no longer improving. He reported decreased visual acuity, due to macular edema, in addition to the peripheral neuropathy, so a decision was made to try the Walkasins® to evaluate its use to maximize his function. The use of the device was approved by the Research Review Board at Wingate University. The patient was fitted with the Walkasins® and was instructed in how to use the sensory information for balance by swaying with the eyes open and closed as well as walking. The patient was able to use the information immediately and improvements in gait and balance measures were noted over time (see Figures 1-3). The patient wore the Walkasins® for more than 2 years while participating in the Neurological Wellness Program sporadically. He was aware of his scores on the outcome measures, completed a home exercise program of gait and balance exercises including encouragement to walk in the community, and received positive feedback as he improved.

Results:
The patient’s improvements in the gait and balance measures assessed before and during the intervention are shown in Figures 1 and 2. Occasional testing occurred with the device turned off. On those occasions, the Walkasins® had been turned off only for that testing day to see if there was carry over. It should be noted that the patient improved his scores beyond the MDC and beyond the fall risk cutoff for each of the outcome measures within the first week of using the device. Surprisingly, the improvements seen with the device in gait and balance appeared to be maintained with the device turned off for one day following 3-4 months of initial use. The patient’s perception of his balance abilities was substantially less when the device was turned off. From a qualitative perspective, the patient reported that the device was easy to use and had greatly improved his balance. He reported that not only had his balance improved but his leg pain and cramping had decreased. He had increased his community ambulation from less than 0.25 miles to over 5 miles. In addition, he had started running down the hallway in the clinic with supervision.

Discussion:

Improvements were seen immediately following donning the Walkasins® and the improvements continued throughout the year follow-up while participating in the exercise program. The patient continues to wear the Walkasins® and maintain improvements, however only the data from the year is presented. These changes were maintained even with the device turned off for 1 day. The most plausible explanation of why he improved was that the Walkasin® provides sensory information from his insensate feet and transferred the information to an area of intact sensation, the calves.
It may also be that the information from the device allowed the brain to align and use other sensory inputs to provide a reference of verticality.

It was unexpected that the Walkasins® may have played a role in decreasing pain and muscle cramping. The mechanism of this is unclear but it is thought that the new relevant sensory information regarding foot pressure provided from Walkasins® may block the allodynia seen with peripheral neuropathy. What is surprising and harder to explain is that the pain relief continued during periods of the day in which the patient was not wearing the device although the increased level of physical activity by the patient may in itself improve his overall health and fitness leading to less pain.

Another unexpected finding was that the gait and balance improvements were seen even when the device was turned off for a day. It may be that the brain learned to use other sensory inputs for postural control. The patient’s perception of his balance abilities decreased as soon as the device was turned off. A possible explanation of the improvements seen with the Walkasins® was due to a placebo effect due to improved confidence. However, this does not seem likely due to his physical performance with the device while turned on. He did know whether the device was on or off during testing as he could tell when it was working. Future research should be conducted to determine what would happen if the device was turned off for longer periods of time. Since the Walkasins® neuroprosthesis attempts to substitute for lost foot pressure sensation required for balance, it may be hypothesized that overall balance function will deteriorate with the device off.

The patient continued to participate in the Neurological Wellness Program while wearing the Walkasins®, making it difficult to determine whether the gait and balance
training or wearing of the Walkasins® made the difference in the outcome measures. It is unlikely that the Neurological Wellness Program made that dramatic of a change as he had participated in the program for 5 months before he was given the Walkasins® and his progress had plateaued. Further research is needed to determine the effect of the Walkasins® on gait and balance in persons with insensitive feet.

Conclusions
The use of the Walkasins® appears to have led to improved gait, balance, and self-perceived stability in a patient with diabetic PN. Using sensory substitution devices may be a new intervention technique for people with gait and balance dysfunction due to PN. Further studies are needed to determine the optimum residual sensory function needed to use the Walkasins® and the need for gait and balance training simultaneously.
References


16. Camargo MR, Barela JA, Nozabieli AJ, Mantovani AM, Martinelli AR, Fregonesi CE. Balance and ankle muscle strength predict spatiotemporal gait parameters in...


48. Cohen HS. Use of the Vestibular Disorders Activities of Daily Living Scale to
49. Marques A, Cruz J, Quina S, Regêncio M, Jácome C. Reliability, Agreement and
Minimal Detectable Change of the Timed Up & Go and the 10-Meter Walk Tests in
50. Combs SA, Diehl MD, Filip J, Long E. Short-distance walking speed tests in
people with Parkinson disease: reliability, responsiveness, and validity. *Gait
51. Ries JD, Echternach JL, Nof L, Gagnon Blodgett M. Test-retest reliability and
minimal detectable change scores for the timed "up & go" test, the six-minute
walk test, and gait speed in people with Alzheimer disease. *Phys Ther.*
52. Hoxie RE, Rubenstein LZ. Are older pedestrians allowed enough time to cross
53. Goldberg A, Schepens S. Measurement error and minimum detectable change in
54. Shumway-Cook A, Woollacott MH. *Motor Control: Theory and Practical
55. Chan AC, Pang MY. Assessing Balance Function in Patients With Total Knee
56. Leddy AL, Crowner BE, Earhart GM. Functional gait assessment and balance
evaluation system test: reliability, validity, sensitivity, and specificity for identifying
57. Marchetti GF, Lin CC, Alghadir A, Whitney SL. Responsiveness and minimal
detectable change of the dynamic gait index and functional gait index in persons
Detectable Change for Sit-to-Stand Tests and the Functional Gait Assessment
59. Walker ML, Austin AG, Banke GM, et al. Reference group data for the functional
60. Wrisley DM, Kumar NA. Functional gait assessment: concurrent, discriminative,
2010;90(5):761-773.
assessment in patients with Parkinson disease: Interrater and intrarater reliability
62. Thieme H, Ritschel C, Zange C. Reliability and validity of the functional gait
assessment (German version) in subacute stroke patients. *Arch Phys Med
Rehabil.* 2009;90(9):1565-1570.
63. Beninato M, Fernandes A, Plummer LS. Minimal clinically important difference
1603.
64. Godi M, Franchignoni F, Caligari M, Giordano A, Turcato AM, Nardone A.
Comparison of reliability, validity, and responsiveness of the mini-BESTest and


A. Activities-specific Balance Confidence Scale

B. Vestibular Activities of Daily Living Score
Figure 1 A. Scores on the Activities-specific Balance Confidence (ABC), B. the Vestibular Activities of Daily Living (VADL), C. Functional Gait Assessment (FGA), D. Mini-BESTest, and E. 20’ Gait Speed prior to and while wearing the Walkasins®. Higher on the ABC, FGA, Mini-Bestest and 20’Gait speed and lower scores on the VADL are better. He started wearing the Walkasins® on 3/8/2017 noted with an arrow ↓. Note that occasionally the Walkasins® device was turned off for a day and on those dates his perception of balance and functional ability decreased.
Figure 2 Patient scores on the Timed “Up & Go” and the Cognitive Timed “Up & Go” in seconds prior to and during intervention with the Walkasins®. He started wearing the Walkasins® 3/8/17 as indicated by the arrow ↓. Note some days
were tested while wearing the device and some were not. When the tests were performed without the Walkasins®, the patient had not used them for one day.